How venture capitalists decide which new medical technologies come to exist

Science and Public Policy

Volumn 43, Issue 3, 2016, Pages 375-385

  Lehoux, P ^a   Miller, F A ^b   Daudelin, G ^a   Urbach, D R ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Academic spin offs; Health policy; Innovation policy; Medical innovation; Sociology of innovation; Venture capital

Indexed keywords

CAPITAL; HEALTH POLICY; INNOVATION; MEDICINE; TECHNOLOGICAL DEVELOPMENT; TECHNOLOGY POLICY;

CANADA; QUEBEC [CANADA];

EID: 84978975698     PISSN: 03023427     EISSN: None     Source Type: Journal    
DOI: 10.1093/scipol/scv051     Document Type: Article

References (41)

1. Ackerly, D. C., Valvered, A. M., Diener, L. W., Dossary, K. L. and Schulman, K. A. (2008) 'Fueling innovation in medical devices (and beyond): Venture capital in health care'. Health Affairs (web exclusive), 68-75.
2. Amit, R., Brander, J. and Zott, C. (1998) 'Why do venture capital firms exist? Theory and Canadian evidence'. Journal of Business Venturing, 13: 441-66.
3. Baum, J. A. and Silverman, B. S. (2004) 'Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups'. Journal of Business Venturing, 19: 411-36.
4. Bertoni, F., Colombo, M. G. and Grilli, L. (2011) 'Venture capital financing and the growth of high-tech start-ups: Disentangling treatment from selection effects'. Research Policy, 40: 1028-43.
5. Buchanan, L. W., Stavropoulos, S. W., Resnick, J. B. and Solomon, J. (2009) 'Endovascular repair of aortic disease: A venture capital perspective'. Seminars in Interventional Radiology, 26: 56-66.
6. Canadian Task Force on Social Finance (2010) Mobilizing Private Capital for Public Good accessed 8 Aug 2015.
7. Chatterji, A. K., Fabrizio, K. R., Mitchell, W. and Schulman, K. A. (2008) 'Physician-industry cooperation in the medical device industry'. Health Affairs, 27: 1532-43.
8. Creswell, J. W. (2013) Research Design: Qualitative, Quantitative, and Mixed Methods Approaches. Thousand Oaks, CA: Sage.
9. Duruflé, G. (2010) Government involvement in the venture capital industry. International comparisons. Report prepared for the Canada's Venture Capital and Private Equity Association. Toronto, Canada: CVCA.
10. Emerson, J. (2003) 'The blended value proposition: Integrating social and financial returns'. California Management Review, 45: 35-51.
11. European Commission (2013) 'Public-private partnerships in Horizon 2020: A powerful tool to deliver on innovation and growth in Europe', COM(2013) 494 final. Brussels: European Commission.
12. Ferlie, E., Fitzgerald, L., Wood, M. and Hawkins, C. (2005) 'The nonspread of innovations: The mediating role of professionals'. Academy of Management Journal, 48: 117-34.
13. Fleming, J. J. (2015) 'The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation'. Health Affairs, 34: 271-6.
14. Flyvbjerg, B. (2011) 'Case study' in The Sage Handbook of Qualitative Research, 4th edition, N. K. Denzin and Y. S. Lincoln (eds), pp. 301-16. Thousand Oaks, CA: Sage.
15. Foray, D., Mowery, D. C. and Nelson, R. R. (2012) 'Public R&D and social challenges: What lessons from mission R&D programs?'. Research Policy, 41: 1697-702.
16. Garber, S., Gates, S. M., Keeler, E. B., Vaiana, M. E. and Mulcahy, A. W. (2014) Redirecting Innovation in US Health Care: Options to Decrease Spending and Increase Value. Santa Monica, CA: RAND Corporation.
17. Gibbert, M. and Ruigrok, W. (2010) 'The ''What'' and ''How'' of case study rigor: Three strategies based on published work'. Organizational Research Methods, 13: 710-37.
18. Grimaldi, R., Kenney, M., Siegel, D. S. and Wright, M. (2011) '30 years after the Bayh-Dole: Reassessing academic entrepreneurship'. Research Policy, 40: 1045-57.
19. Hirsch-Kreinsen, H. (2011) 'Financial market and technological innovation'. Industry and Innovation, 18: 351-68.
20. Horizon 2020 (2013) 'Access to risk finance'. Work Programme 2014-2015. (European Commission Decision C (2013)8631 of 10 December 2013) accessed 2 Sep 2014.
21. Lazonick, W. and Mazzucato, M. (2013) 'The risk-reward nexus in the innovation-inequality relationship: Who takes the risks? Who gets the rewards?'. Industrial and Corporate Change, 2: 1093-128.
22. Lazonick, W. and Tulum, O. (2011) 'US biopharmaceutical finance and the sustainability of the biotech business model'. Research Policy, 40: 1170-87.
23. Lehoux, P., Daudelin, G., Hivon, M., Miller, F. A. and Denis, J.-L. (2014a) 'How do values shape technology design? An exploration of what makes the pursuit of health and wealth legitimate in academic spin-offs'. Sociology of Health ands Illness, 36: 738-55.
24. Lehoux, P., Daudelin, G.,Williams-Jones, B., Denis, J.-L. and Longo, C. (2014b) 'How do business models and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs'. Research Policy, 43: 1025-38.
25. Lehoux, P., Miller, F. A., Hivon, M., Demers-Payette, O. and Urbach, D. (2013) 'Clinicians as health technology designers: Two contrasting tales about user involvement in innovation development'. Health Technology and Policy, 2: 122-30.
26. Lehoux, P., Williams-Jones, B., Miller, F. A., Urbach, D. and Tailliez, S. (2008) 'What leads to better health innovation? Arguments for an integrated policy-oriented research agenda'. Journal of Health Services Research and Policy, 13: 251-4.
27. Leonardi, P. M. and Barley, S. R. (2010) 'What's under construction here? Social action, materiality, and power in constructivist studies of technology and organizing'. Academy of Management Annals, 4: 1-51.
28. Lerner, J. and Ta°g, J. (2013) 'Institutions and venture capital'. Industrial and Corporate Change, 22: 153-82.
29. Luukkonen, T., Deschryvere, M. and Bertoni, F. (2013) 'The value added by government venture capital funds compared with independent venture capital funds'. Technovation, 33: 154-62.
30. MedTech Europe (undated) 'The European medical technology industry in figures' accessed 2 Sep 2014.
31. Oakey, R. P. (2003) 'Funding innovation and growth in UK new technologybased firms: Some observations on contributions from the public and private sectors'. Venture Capital: An International Journal of Entrepreneurial Finance, 5: 161-79.
32. Pierrakis, Y. (2010) Venture Capital Now and After the Dotcom Crash. London: National Endowment for Science, Technology and the Arts.
33. Robinson, J. C. (2015) 'Biomedical innovation in the era of health care spending constraints'. Health Affairs, 34: 203-9.
34. Sabatier, V., Craig-Kennard, A. and Mangematin, V. (2012) 'When technological discontinuities and disruptive business models challenge dominant industry logics: Insights from the drugs industry'. Technological Forecasting and Social Change, 79: 949-62.
35. Sampat, B. and Drummond, M. (2011) 'Another special relationship? Interactions between health technology policies and health care systems in the United States and the United Kingdom'. Journal of Health Politics, Policy and Law, 36: 119-39.
36. Scott, W. R. (2008) 'Approaching adulthood: The maturing of institutional theory'. Theory and Society, 37: 427-42.
37. Song, M., Podoynitsyna, K., van der Bij, H. and Halman, J. I. (2008) 'Success factors in new ventures: A meta analysis'. Journal of Product Innovation Management, 25: 7-27.
38. Styhre, A. (2014) 'Coping with the financiers: Attracting venture capital investors and end-users in the biomaterials industry'. Technology Analysis and Strategic Management, 26: 797-809.
39. Tucker, J., Chakma, J., Fedak, P. W. and Cimini, M. (2011) 'Catalyzing capital for Canada's life sciences industry'. Journal of Commercial Biotechnology, 17: 330-48.
40. Vohora, A., Wright,M. and Lockett, A. (2004) 'Critical junctures in the development of university high-tech spinout companies'. Research Policy, 33: 147-75.
41. Zider, B. (1998) 'How venture capital works'. Harvard Business Review, 76: 131-9.